Skip to main content
main-content

The continuing evolution of GLP-1RAs

Glucagon-like peptide 1 receptor agonists in type 2 diabetes: Their use and differential features

Learn about the appropriate uses and benefits of GLP‑1RAs in the treatment of type 2 diabetes. Read the full-text article:

Learning objectives

Following participation in these educational activities, you will be able to:

  1. Discuss the importance of timely treatment of type 2 diabetes and its impact on patient health and outcomes.
  2. Compare the efficacy and safety profiles of once weekly GLP-1RAs.
  3. Explain the next generation of GLP-1RAs including the mode of absorption, mechanism of action, dosing schedule, pharmacokinetic/pharmacodynamic properties, glycemic/weight loss efficacy and safety.

Target audience

These learning activities are suitable for, but not limited to, diabetes specialists, primary care physicians, specialist diabetes nurses, cardiologists, and all other healthcare professionals interested in the treatment of type 2 diabetes.

Accreditation

An application has been made to the UEMS EACCME® for CME accreditation of the English version of the webcast.

Educational funding

This program is made possible thanks to an independent educational grant from Novo Nordisk A/S.

Contact us

Email: IME@springer.com
Springer Healthcare IME
The Campus, 4 Crinan Street
London, N1 9XW, UK 


Springer Healthcare IME logo © Springer Healthcare

Image Credits